相关实验视频
Updated: May 23, 2025

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
84.6K
缺氧诱导因子-1α驱动癌症对cuproptosis的抗性
Zhou Yang1, Wei Su2, Xiyi Wei3
1Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cancer cell
|March 7, 2025
概括
缺氧诱导因子-1α (HIF-1α) 通过影响蛋白质脂解和铜代谢,在固体瘤中驱动对铜相关的细胞死亡 - - 铜亡的抗性. 抑制HIF-1α可以增加癌症对cuproptosis的敏感性.
科学领域:
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
- 代谢过程中的代谢.
背景情况:
- 型亡是一种新型细胞死亡途径,与铜恒温和蛋白质化有关.
- 在低氧瘤微环境 (TME) 中,cuproptosis被抑制.
研究的目的:
- 为了研究缺氧诱导因子-1α (HIF-1α) 在固体瘤中对cuproptosis耐药性的作用.
- 为了阐明HIF-1α在缺氧下促进对cuproptosis的抵抗的分子机制.
主要方法:
- 研究了HIF-1α对酸盐脱酶激酶 (PDK1/3) 和二利胺 S-乙酸转移酶 (DLAT) 表达的作用.
- 评估了金属氨酸在线粒体铜封存中的作用.
- 研究了高铜含量对HIF-1α蛋白稳定性和无处不在性的影响.
- 评估了HIF-1α抑制对癌症对cuproptosis敏感性的体内疗效.
主要成果:
- HIF-1α激活导致DLAT表达减少和金属氨酸增加,隔离线粒体中的铜,并赋予cuproptosis耐药性.
- 高水平的铜稳定HIF-1α蛋白,减少其无处不在.
- 抑制HIF-1α显著增加了癌症在体内对cuproptosis的敏感性.
结论:
- 在低氧条件下,HIF-1α是固体瘤中对cuproptosis耐药性的关键驱动因素.
- 这项研究揭示了一种新的分子机制,将低氧,HIF-1α和铜代谢与致癌和亡逃避联系起来.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Electron Transport Chain: Complex I and II
10.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.0K

